Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 5 | 2022 | 45 | 1.970 |
Why?
|
| Conditioning, Operant | 6 | 2021 | 6 | 1.850 |
Why?
|
| Sex Characteristics | 4 | 2018 | 26 | 1.680 |
Why?
|
| Animals | 20 | 2023 | 1711 | 1.530 |
Why?
|
| Methamphetamine | 4 | 2020 | 4 | 1.450 |
Why?
|
| Paternal Exposure | 2 | 2022 | 2 | 1.380 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 19 | 1.330 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 27 | 1.240 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2019 | 22 | 1.190 |
Why?
|
| Central Nervous System Stimulants | 2 | 2020 | 8 | 1.180 |
Why?
|
| Anxiety | 3 | 2022 | 167 | 1.150 |
Why?
|
| Alcoholism | 2 | 2021 | 42 | 1.130 |
Why?
|
| Rats | 9 | 2022 | 241 | 1.020 |
Why?
|
| DNA Methylation | 3 | 2021 | 27 | 0.980 |
Why?
|
| Male | 14 | 2023 | 2491 | 0.980 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2019 | 14 | 0.970 |
Why?
|
| Pituitary-Adrenal System | 4 | 2019 | 14 | 0.970 |
Why?
|
| Self Administration | 6 | 2021 | 7 | 0.920 |
Why?
|
| Stress, Psychological | 4 | 2019 | 86 | 0.890 |
Why?
|
| Receptors, GABA-B | 2 | 2021 | 2 | 0.840 |
Why?
|
| Female | 10 | 2023 | 2523 | 0.820 |
Why?
|
| Drug Overdose | 1 | 2023 | 6 | 0.800 |
Why?
|
| Brain | 4 | 2020 | 195 | 0.790 |
Why?
|
| Semen | 1 | 2022 | 1 | 0.770 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 34 | 0.750 |
Why?
|
| Pyrimidines | 1 | 2021 | 6 | 0.700 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 12 | 0.700 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2021 | 19 | 0.700 |
Why?
|
| Food | 1 | 2021 | 1 | 0.690 |
Why?
|
| Microbiota | 1 | 2021 | 14 | 0.690 |
Why?
|
| Cocaine | 1 | 2021 | 5 | 0.690 |
Why?
|
| Appetitive Behavior | 2 | 2018 | 2 | 0.660 |
Why?
|
| Consummatory Behavior | 2 | 2018 | 2 | 0.660 |
Why?
|
| Behavior, Animal | 1 | 2020 | 20 | 0.660 |
Why?
|
| Central Nervous System Depressants | 2 | 2017 | 7 | 0.650 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 102 | 0.640 |
Why?
|
| Environmental Exposure | 1 | 2019 | 10 | 0.610 |
Why?
|
| Behavior, Addictive | 1 | 2019 | 8 | 0.600 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 47 | 0.580 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2021 | 125 | 0.570 |
Why?
|
| Naltrexone | 1 | 2018 | 1 | 0.560 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 52 | 0.550 |
Why?
|
| Fenofibrate | 1 | 2017 | 1 | 0.520 |
Why?
|
| PPAR alpha | 1 | 2017 | 1 | 0.520 |
Why?
|
| Alcohol Deterrents | 1 | 2017 | 2 | 0.510 |
Why?
|
| Motor Activity | 1 | 2017 | 61 | 0.500 |
Why?
|
| Humans | 7 | 2023 | 4936 | 0.490 |
Why?
|
| Neurons | 3 | 2017 | 109 | 0.350 |
Why?
|
| Dysbiosis | 2 | 2021 | 2 | 0.340 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 4 | 2018 | 4 | 0.320 |
Why?
|
| Rats, Wistar | 2 | 2021 | 31 | 0.300 |
Why?
|
| Pregnancy | 2 | 2019 | 89 | 0.300 |
Why?
|
| Reinforcement Schedule | 2 | 2018 | 2 | 0.270 |
Why?
|
| Tetanus Toxoid | 2 | 2019 | 2 | 0.270 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2019 | 2 | 0.270 |
Why?
|
| Dietary Sucrose | 2 | 2017 | 2 | 0.260 |
Why?
|
| Corticosterone | 4 | 2018 | 19 | 0.230 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2018 | 5 | 0.220 |
Why?
|
| Fentanyl | 1 | 2023 | 1 | 0.200 |
Why?
|
| Sex Factors | 1 | 2023 | 76 | 0.200 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 73 | 0.190 |
Why?
|
| Aluminum Hydroxide | 2 | 2019 | 2 | 0.180 |
Why?
|
| Prebiotics | 1 | 2021 | 3 | 0.180 |
Why?
|
| Nucleus Accumbens | 1 | 2021 | 7 | 0.180 |
Why?
|
| Baclofen | 1 | 2021 | 1 | 0.180 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2021 | 1 | 0.180 |
Why?
|
| Morpholines | 1 | 2021 | 3 | 0.180 |
Why?
|
| Allosteric Regulation | 1 | 2021 | 7 | 0.180 |
Why?
|
| Extinction, Psychological | 1 | 2021 | 1 | 0.170 |
Why?
|
| Rats, Inbred Lew | 1 | 2021 | 1 | 0.170 |
Why?
|
| Species Specificity | 1 | 2021 | 14 | 0.170 |
Why?
|
| Rats, Inbred F344 | 1 | 2021 | 21 | 0.170 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 34 | 0.170 |
Why?
|
| Swimming | 1 | 2020 | 4 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 17 | 0.170 |
Why?
|
| Feces | 1 | 2020 | 26 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 69 | 0.150 |
Why?
|
| Phospholipids | 1 | 2019 | 4 | 0.150 |
Why?
|
| Depression | 1 | 2020 | 125 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2018 | 1 | 0.140 |
Why?
|
| Diestrus | 1 | 2018 | 1 | 0.140 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 10 | 0.140 |
Why?
|
| Stress, Physiological | 1 | 2018 | 26 | 0.140 |
Why?
|
| Drug-Seeking Behavior | 1 | 2017 | 1 | 0.130 |
Why?
|
| Locomotion | 1 | 2017 | 11 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 21 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 58 | 0.130 |
Why?
|
| KCNQ Potassium Channels | 1 | 2016 | 1 | 0.130 |
Why?
|
| Solute Carrier Family 12, Member 2 | 1 | 2016 | 1 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 6 | 0.120 |
Why?
|
| Neural Inhibition | 1 | 2016 | 5 | 0.120 |
Why?
|
| Vaccination | 1 | 2015 | 4 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 225 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 2 | 2019 | 5 | 0.070 |
Why?
|
| Mice | 2 | 2019 | 685 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 10 | 0.040 |
Why?
|
| Biological Availability | 1 | 2019 | 14 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 24 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 25 | 0.040 |
Why?
|
| Hypothalamus | 1 | 2018 | 1 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 177 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2018 | 18 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2017 | 6 | 0.030 |
Why?
|
| Adenylate Kinase | 1 | 2016 | 1 | 0.030 |
Why?
|
| KCNQ3 Potassium Channel | 1 | 2016 | 1 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2016 | 7 | 0.030 |
Why?
|
| Bumetanide | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 1 | 0.030 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2016 | 1 | 0.030 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pyridazines | 1 | 2016 | 3 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 2 | 0.030 |
Why?
|
| Muscimol | 1 | 2016 | 3 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2016 | 16 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 28 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2015 | 9 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 28 | 0.030 |
Why?
|